CADL – candel therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409 [Yahoo! Finance]
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors [Yahoo! Finance]
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Candel Therapeutics (CADL) had its price target lowered by Citigroup Inc. from $24.00 to $22.00. They now have a "buy" rating on the stock.
Candel Therapeutics (CADL) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $25.00 price target on the stock.
Form SCHEDULE 13D/A Candel Therapeutics, Filed by: Manning Paul B
Form S-8 Candel Therapeutics,
Form 10-K Candel Therapeutics, For: Dec 31
Form 8-K Candel Therapeutics, For: Mar 12
Form 4 Candel Therapeutics, For: Feb 23 Filed by: Manning Paul B
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.